脳震盪市場

The secondary research process involved comprehensive analysis of neurological health databases, traumatic brain injury (TBI) surveillance systems, peer-reviewed neurotrauma journals, clinical neurology publications, and authoritative health organizations. Key sources included the US Centers for Disease Control and Prevention (CDC) Traumatic Brain Injury Surveillance System, National Center for Injury Prevention and Control (NCIPC), US Food & Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) 510(k) clearances for neurodiagnostic devices, National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS), National Center for Biotechnology Information (NCBI/PubMed) database for concussion biomarker studies, World Health Organization (WHO) Neurology and Brain Health Atlas, Brain Injury Association of America (BIAA) statistical reports, European Brain Injury Consortium (EBIC), Organisation for Economic Co-operation and Development (OECD) Health Statistics, EU Eurostat Health Database, National Collegiate Athletic Association (NCAA) Injury Surveillance Program, National Athletic Trainers' Association (NATA) position statements, and national neurotrauma registries from key markets including the Canadian Brain Injury Association, UK National Health Service (NHS) Digital TBI statistics, and Australian Institute of Health and Welfare (AIHW) brain injury reports. These sources were utilized to collect TBI incidence and prevalence data, concussion diagnosis protocol statistics, regulatory approval pathways for neurodiagnostic devices, clinical safety and efficacy studies for imaging technologies and biomarkers, sports-related concussion trends, military TBI surveillance data, reimbursement coding dynamics (CPT/ICD-10), and market landscape analysis for advanced diagnostic technologies including quantitative EEG, functional near-infrared spectroscopy (fNIRS), blood biomarker assays (GFAP, UCH-L1), and magnetic resonance imaging (MRI) sequences.

During the primary research process, qualitative and quantitative insights regarding concussion diagnosis and management protocols were obtained through interviews with supply-side and demand-side stakeholders. The supply-side sources consisted of CEOs, VPs of R&D, regulatory affairs directors, and commercial leaders from neurodiagnostic device manufacturers, medical imaging companies, and concussion biomarker developers. Board-certified neurologists, neurosurgeons, emergency medicine physicians, sports medicine specialists, athletic trainers, and procurement directors from level I trauma centers, academic medical centers, sports medicine clinics, rehabilitation facilities, and hospital radiology departments comprised demand-side sources. Primary research has confirmed the product development timelines for portable concussion assessment devices, validated market segmentation across diagnostic modalities (imaging, biomarkers, neurocognitive testing), and gathered insights on clinical adoption patterns of point-of-care testing, pricing strategies for wearable monitoring devices, and reimbursement dynamics for concussion protocols.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (31%), Others (37%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Global market valuation was derived through revenue mapping of diagnostic device portfolios and concussion management procedure volume analysis. The methodology included:

Identification of 40+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America specializing in neuroimaging equipment, portable diagnostic devices, biomarker testing platforms, and concussion management software

Product mapping across diagnostic technologies (CT/MRI imaging, quantitative EEG, fNIRS, ocular tracking, blood biomarker assays) and treatment modalities (neuromodulation devices, pharmacological interventions, rehabilitation protocols)

Analysis of reported and modeled annual revenues specific to concussion/TBI product portfolios, including FDA-cleared and CE-marked neurodiagnostic devices

Coverage of manufacturers representing 75-80% of global market share in 2024, with particular emphasis on companies developing AI-integrated concussion assessment platforms and wearable impact sensors

Extrapolation using bottom-up (procedure volume × ASP by country/setting, segmented by emergency department visits, sports medicine clinics, and military screening programs) and top-down (manufacturer revenue validation, distributor channel analysis) approaches to derive segment-specific valuations for diagnosis and treatment markets